Gsk Share Discussion Threads

[waldron] 11/5/2022 12:56

27 July 2022 Announcement of Q2 2022 results
2 November 2022 Announcement of Q3 2022 results
1 February 2023 Announcement of Q4 2022 results

[jretlaw] 11/5/2022 12:53

Gsk is heavenly discounted at this price soon we will see a drastic race between funds to get in on the action 20 pounds herd we come im buying big time

[abdullla] 09/5/2022 14:40

Correct, thanks

[tradermichael] 09/5/2022 12:20

Further to my message ref. 29673, I have had an update from my broker who now states that the demerger will be complete by mid July 2022 (as most of us know).

[spyder] 07/5/2022 12:39

Good point TM, although .... this isn't really a float in the traditional sense.
I am a bit confused about how it will work exactly, but as I understanding ~1/3 of Haleon (the name is growing on me) belongs to Pfizer and ~2/3 to GSK and the shares will be apportioned accordingly and in GSK's case, 80% of the 2/3 will be passed on to (us) shareholders.
I presume there are no new shares being issued/funds raised, or perhaps there will be?
I know the Execs have been courting sovereign wealth funds etc, so I guess there may be an element of investment required at IPO, or is it more to do with ensuring a health demand for shares post IPO for those current shareholders who don't want to hold Haleon stock?

[tradermichael] 07/5/2022 08:32

The Nasdaq is now in a “bear market” after falling 22pc since the start of the year. April was its worst month since the 2008 financial crisis. The broader S&P 500 shed almost 4pc as the sell-off spread to other stocks, erasing about $1.3 trillion of market value.

TRADITIONALLY, THIS IS NOT A GOOD TIME TO FLOAT A NEW COMPANY!

[patientcapital] 07/5/2022 08:32

From GSK FAQs page on their website:"2. When is the demerger taking place?The demerger and listing of Haleon is expected to take place in July 2022."

[tradermichael] 07/5/2022 08:20

That's what I thought so I checked twice with AJ Bell and they gave out the same dates. I still believe July 2022 is correct. I have asked my broker to double check with Glaxo.

[abdullla] 06/5/2022 17:48

Not true and not possible,besides no body has received any correspondence from GSK.

[tradermichael] 06/5/2022 12:24

I had a note from my broker who has received information from GSK:

"The demerger is now expected to complete in mid-May 2022."
(Seems to conflict with earlier news from GSK elsewhere).

[tradermichael] 05/5/2022 10:51

Sierra Oncology was ready to take momelotinib to the market, but it needed help. What started out as an effort to find a strategic partner turned into a $1.9 billion buyout from GlaxoSmithKline, which didn’t just want an arm's-length deal. Chief Commercial Officer Luke Miels wanted it all.

The details of the deal, announced April 12, were revealed in a proxy document (PDF) issued by Sierra Monday. The regulatory filing shows the back and forth of the transaction, which had multiple parties involved. But none, ultimately, could match GSK's interest and quickly climbing offer.

The saga began when Sierra engaged an investment bank in December 2021 to pursue a sale, licensing, partnership or other transaction to help with commercialization of momelotinib.

This January, Sierra announced that momelotinib relieved anemia symptoms and splenic size during the phase 3 MOMENTUM trial in myelofibrosis. The results teed up an FDA filing for the second quarter of this year. Sierra also conducted a public offering of stock that went on to raise $145.3 million at this time. This cash would be used to finance the therapy's commercialization and clinical development for Sierra’s other pipeline candidates.

Miels returned with an offer of $51 per share on March 11, which triggered outreach to the 10 additional companies. Four immediately declined to continue, but six unnamed companies were interested. One company, referred to as Party B, was deep into discussions on a potential strategic partnership and promised to send in an acquisition proposal. The offer ended up being $40 per share, well below what GSK was putting forward.
The outreach with the existing companies involved continued, but the board decided not to engage any new ones. Party B was told to put up more, while presentations were made to another company, Party A. Meanwhile, the due diligence process with GSK kicked into high gear.

Party B ultimately declined to revise its offer, despite a last-ditch effort on March 22 by a company representative to change Dilly’s mind. The company backed off but said to keep in touch if the other offers fell through.

Three more companies entered the fray, but those negotiations did not go anywhere. Parties A and C also dropped out by the end of March.

Miels and Dilly met once again on March 26, and Sierra asked for another revised offer. Miels returned on April 2 with $55 per share, the last GSK proposal, setting off a period of exclusivity. Sierra canceled at least one meeting with Party F, which had still been in the M&A running, and others that were still interested in strategic partnerships.

The terms of the deal were hammered out on April 4, and, by April 13, the deal was announced.

[waldron] 04/5/2022 18:57

GlaxoSmithKline PLC said Wednesday that the resolution to approve its directors' remuneration report passed at its general meeting with a low vote count, noting that it will continue explaining the rationale for the changes to shareholders.

The British pharma major said that the resolution only got the support of 61.76% of the vote count.

"The company undertook an in-depth consultation process with the majority of its largest shareholders in developing the revised policy and will continue to engage to ensure it fully understands the views of all shareholders on these matters," the FTSE 100 listed company said.



Write to Sabela Ojea at [e-mail]; @sabelaojeaguix



(END) Dow Jones Newswires

May 04, 2022 13:28 ET (17:28 GMT)

[tradermichael] 04/5/2022 14:18

I think 2100p is easily achievable. Either way, Haleon will become one of the biggest listed companies in Britain, with a market capitalisation that will place it in the top 20% of the FTSE-100 index. Having rejected Unilever's offer of £50bn, the GSK and Pfizer boards must be confident that a premium will emerge with a full listing for their Consumer Healthcare business (the biggest new arrival on the London stock market for at least a decade)... ;0)

[alibizzle] 03/5/2022 22:44

If it goes to £21 pre split I'll sell even though CH shares might double post split with a large bid

[patientcapital] 30/4/2022 13:02

With Sterling weakening again our companies are looking ever more attractive to the overseas buyer not that I would be at all sanguine about seeing yet more of them falling into foreign hands. Something of a bittersweet double edged sword.

[tradermichael] 30/4/2022 10:35

Yes, and there could be some predator companies out there on the acquisition trail .... ;0)

[netcurtains] 30/4/2022 08:17

Its all quite exciting.
I should expect demand for the shares
will hot up as we approach the split date.
Lots of people always want shares in brand
new FTSE100 companies. And this time you
get TWO.

[tradermichael] 30/4/2022 07:37

The details of the 'split' will be released in June and, subject to a shareholder vote of acceptance, the split will take place in July with holders of 'n' shares receiving 'n' shares in New GSK and 'n' shares in Haleon.

The Q1 dividend will be 14p per existing GSK share held on 18 May.

[alibizzle] 29/4/2022 20:29

Will the next dividend in may be at the new lower price ? Also if I have 2000 shares now , come the split will i get 2000 shares in new gsk And 2000 shares in CH?

[tradermichael] 29/4/2022 14:51

USD 1.25 = £1.00

[tradermichael] 29/4/2022 11:42

xd Q1 in 3 weeks .... 14p per share

[tradermichael] 29/4/2022 11:42

xd Q1 in 3 weeks .... 14p per share

[tradermichael] 29/4/2022 11:41

xd Q1 in 3 weeks .... 14p per share

[tradermichael] 29/4/2022 10:13

GlaxoSmithKline PLC said Friday that a Covid-19 vaccine developed with South Korea-based SK Bioscience Co. has met its co-primary objectives in a Phase 3 study, demonstrating superior antibody levels compared with AstraZeneca PLC's shot, which was chosen as a control vaccine. The British pharmaceutical major said that the vaccine, which is called SKYCovione and uses Glaxo's adjuvant technology, showed a clinically acceptable safety profile, with most postvaccine adverse reactions being mild or moderate. SK Bioscience will apply for emergency-use listing with the World Health Organization and authorization at individual regulatory agencies around the world. The company had already signed an advance purchase agreement with South Korea for a total of 10 million doses, Glaxo said.

Write to Cecilia Butini at [e-mail] (END) Dow Jones Newswires April 29, 2022 04:08 ET (08:08 GMT)